KLK4
Aliases:
This biomarker is also known as:- Serine protease 17
- Enamel matrix serine proteinase 1
- EMSP1
- PRSS17
- Prostase
- Kallikrein-4
- hK4
- KLK4
- KLK-L1
- Human kallikrein 4
- PSTS
- Kallikrein-like protein 1
Description…
The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Several human kallikrein genes have been isolated. hK4 is expressed in the prostate.
Datasets
There are no datasets associated with this biomarker.
Attributes
QA State: | Accepted |
---|---|
Type: | Protein |
HGNC Name: | KLK4 |
The following organs have data associated with this biomarker…
Attributes
Phase: | 2 |
---|---|
QA State: | Accepted |
Overview
Kallikreins (KLKs) are highly conserved serine proteases that play key roles in a variety of physiological and pathological processes. KLK4 is regulated by androgens and is highly specific to prostate for expression. hK4 is intracellularly localized. KLK4 is predominantly expressed in the basal cells of the normal prostate gland and overexpressed in prostate cancer. hK4 has a unique structure and function compared with other members of the KLK family and may have a role in the biology and characterization of prostate cancer.
Performance Comment
hK2, hK4 and hK11 do not distinguish cases from controls in these populations.
Supporting Study Data
The following studies/protocols provide evidence supporting KLK4 indications for the Prostate…
Prostate Rapid Pre-Validation Set
Determine which markers move to validation using the prospectie prostate reference set samples.
View more about this studyBiomarker Characteristics Summary
No statistics found.
Decision Rule
No clinically useful decision rule found.
Additional Study-Specific Protocols
Study-Specific Publications
No study-specific publications defined.
Study-Specific Resources
No study-specific resources defined.
Prostate Rapid Reference Set Application: Brian Haab - Van Andel (2006)
To evaluate TSP-1 as a marker to specifically detect prostate cancer
View more about this studyBiomarker Characteristics Summary
No statistics found.
Decision Rule
No extra decision rule information available
Additional Study-Specific Protocols
Study-Specific Publications
No study-specific publications defined.
Study-Specific Resources
No study-specific resources defined.
Prostate Rapid Reference Set Application: Eleftherios Diamandis - Mt Sinai (2006)
A blinded study coordinated by the EDRN GU Collaborative Group found the biomarker is not associated with prostate cancer risk
View more about this studyBiomarker Characteristics Summary
No statistics found.
Decision Rule
No clinically useful decision rule found.
Additional Study-Specific Protocols
Study-Specific Publications
No study-specific publications defined.
Study-Specific Resources
No study-specific resources defined.
Prostate Reference Set Application: proPSA-Dan Chan-JHU (2008)
Primary Objective – To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary biopsies.
View more about this studyBiomarker Characteristics Summary
No statistics found.
Decision Rule
No extra decision rule information available
Additional Study-Specific Protocols
Study-Specific Publications
No study-specific publications defined.
Study-Specific Resources
No study-specific resources defined.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
- Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans.
- An Approach To Fabricate PDMS Encapsulated All-Solid-State Advanced Asymmetric Supercapacitor Device with Vertically Aligned Hierarchical Zn-Fe-Co Ternary Oxide Nanowire and Nitrogen Doped Graphene Nanosheet for High Power Device Applications.